Esperion Update On Lead Cholestrol Drug Spooks Investors

Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday.